Clinical trials: Idiopathic Multicentric Castleman's Disease
Idiopathic Multicentric Castleman's Disease
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.
- Trial name
- NCT03982771
- Testing
- Bortezomib, Cyclophosphamide, Dexamethason
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Idiopathic Multicentric Castleman's Disease
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
- Trial name
- SISREMCAD (NCT04838860)
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RECORDATI GROUP
Idiopathic Multicentric Castleman's Disease
Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)
Development, validation of a novel symptom burden scale to assess and quantify the burden experienced by people living with Idiopathic Multicentric Castleman Disease (iMCD).
- Trial name
- NCT05995834
- Testing
- Research questions
- Volunteers
- 100 people
- Sponsor
- RECORDATI GROUP
Idiopathic Multicentric Castleman's Disease
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
This study is a single-arm, open-label, multicenter, dose-escalation clinical study. Its primary purpose is to evaluate the safety and tolerability of recombinant humanized anti-interleukin-6 receptor monoclonal antibody …
- Trial name
- NCT05345522
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Beijing VDJBio Co., LTD.
Castleman Disease, Angiofollicular Lymphoid Hyperplasia
Unlock the Cell: Castleman's Disease Flow Cytometry Study
Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction.
- Conditions
- Castleman Disease, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia
- Trial name
- NCT02853968
- Testing
- Blood draw/buccal swab
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Idiopathic Multicentric Castleman's Disease
Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
To explore the effectiveness and safety of Zanuburutinib in relapsed and refractory idiopathic Multicentric Castleman's disease (iMCD) patients.
- Trial name
- iMCD (NCT04743687)
- Testing
- Zanubrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those…
- Trial name
- NCT07085039
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Pennsylvania
Anti IL-6R, Castleman's Disease, Multicentric
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to…
- Trial name
- NCT07872423
- Testing
- Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 8 sites in China
- Volunteers
- 45 people
- Sponsor
- Beijing VDJBio Co., LTD.
Castleman Disease, Castleman's Disease, Multicentric
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
- Trial name
- NCT03933904
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania